Cyclin-dependent kinase 4 expression is essential for neu-induced breast tumorigenesis.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Cancer Research

• Publication date

  2005-11-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-05-2639PMID 16288002
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The role of the cyclin D1-dependent kinases in ErbB2-mediated breast cancer.

  2004cited by this paper
• Mouse development and cell proliferation in the absence of D-cyclins.

  2004cited by this paper
• A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer.

  2003cited by this paper
• Cdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescence.

  2002cited by this paper
• Germ Line Transmission of the Cdk4R24C Mutation Facilitates Tumorigenesis and Escape from Cellular Senescence

  2002cited by this paper
• The Restriction Point of the Cell Cycle

  2002cited by this paper
• Specific protection against breast cancers by cyclin D1 ablation

  2001influential reference
• To cycle or not to cycle: a critical decision in cancer

  2001cited by this paper
• The Pezcoller lecture: cancer cell cycles revisited.

  2000cited by this paper
• Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in β-islet cell hyperplasia

  1999cited by this paper
• Cyclin-dependent kinases: engines, clocks, and microprocessors.

  1997cited by this paper
• Cyclin D1 and prognosis in human breast cancer

  1996cited by this paper
• Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs).

  1995cited by this paper
• Determination of the prognostic value of cyclin D1 overexpression in breast cancer.

  1995cited by this paper
• Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer.

  1995cited by this paper
• Mice lacking cyclin D1 are small and show defects in eye and mammary gland development.

  1995cited by this paper
• Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions

  1995cited by this paper
• Cyclin D1 protein expression and function in human breast cancer

  1994cited by this paper
• Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice

  1994cited by this paper
• Expression and amplification of cyclin genes in human breast cancer.

  1993cited by this paper
• D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1.

  1991cited by this paper
• Molecular oncology

  1991cited by this paper
• Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice.

  1988cited by this paper
• Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene.

  1988cited by this paper

• CDK4/6 Inhibitor Resistance in ER+ Breast Cancer.

  2025cites this paper
• CDK4/6 inhibitors synergize with radiotherapy to prime the tumor microenvironment and enhance the antitumor effect of anti-PD-L1 immunotherapy in triple-negative breast cancer

  2025cites this paper
• Assessment of In Vitro Assays and Quantitative Determination of Selectivity and Modality of Inhibitors Targeting the Cell Cycle Regulating, Oncogenic Cyclin-Dependent Kinases.

  2025cites this paper
• Durable and Drastic Response to the Trastuzumab, Letrozole, Abemaciclib, and Goserelin Combination as First-Line Therapy in HER2-Positive and Hormone Receptor-Positive Metastatic Breast Cancer: A Case Report

  2025cites this paper
• Chromosome 8 Open Reading Frame 76 (C8orf76) Co-Expressed with Cyclin-Dependent Kinase 4 (CDK4) as a Prognostic Indicator of Colorectal Cancer.

  2025cites this paper
• Exploration of the potential molecular mechanism of magnolol in colorectal cancer treatment based on network pharmacology and molecular docking

  2025cites this paper
• The deubiquitinase USP7 stabilizes HER2 expression and promotes breast cancer progression

  2025cites this paper
• Novel indolyl 1,2,4-triazole derivatives as potential anti-proliferative agents: in silico studies, synthesis, and biological evaluation.

  2024cites this paper
• Radiosensitizing effects of CDK4/6 inhibitors in hormone receptor-positive and HER2-negative breast cancer mediated downregulation of DNA repair mechanism and NF-κB-signaling pathway

  2024cites this paper
• Cancer invasion and metastasis: Insights from murine pubertal mammary gland morphogenesis.

  2023cites this paper
• Science Journals — AAAS

  2022cites this paper
• CDK4 and CDK6 kinases: From basic science to cancer therapy

  2022cites this paper
• CDK4: a master regulator of the cell cycle and its role in cancer

  2022cites this paper
• Role of hydrogen sulfide donors in cancer development and progression

  2021cites this paper
• Elucidating the Unknown Role of Cyclin Dependent Kinase 5 in Cardiac Pathophysiological Conditions

  2021cites this paper
• The evolution of cyclin dependent kinase inhibitors in the treatment of cancer

  2021cites this paper
• Aminoacyl-tRNA Synthetases and amino acid signaling.

  2020cites this paper
• FUCCI Real-Time Cell-Cycle Imaging as a Guide for Designing Improved Cancer Therapy: A Review of Innovative Strategies to Target Quiescent Chemo-Resistant Cancer Cells

  2020cites this paper
• Senescence as a therapeutically relevant response to CDK4/6 inhibitors

  2020cites this paper
• Less-well known functions of cyclin/CDK complexes.

  2020cites this paper
• Testicular torsion and reperfusion: Germ cell DNA damage and development

  2019cites this paper
• Mammalian Development and Cancer: A Brief History of Mice Lacking D-Type Cyclins or CDK4/CDK6

  2018cites this paper
• Targeting the cell cycle in breast cancer: towards the next phase

  2018cites this paper
• Stabilization of Cyclin-Dependent Kinase 4 by Methionyl-tRNA Synthetase in p16INK4a-Negative Cancer.

  2018cites this paper
• The D-Type Cyclins: A Historical Perspective

  2018cites this paper
• Cell cycle proteins as promising targets in cancer therapy

  2017cites this paper
• Antioxidant, Anti-inflammatory, and Genomic Stability Enhancement Effects of Zinc l-carnosine: A Potential Cancer Chemopreventive Agent?

  2017cites this paper
• Mechanisms of therapeutic CDK4/6 inhibition in breast cancer.

  2017cites this paper
• Targeting the CDK4/6 Pathway in Breast Cancer

  2017cites this paper
• Progress with palbociclib in breast cancer: latest evidence and clinical considerations

  2017cites this paper
• Preclinical characterization of abemaciclib in hormone receptor positive breast cancer

  2017cites this paper
• CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update

  2016cites this paper
• Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers

  2016cites this paper
• CDK6—a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation

  2016cites this paper
• Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016)

  2016cites this paper
• Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.

  2016cites this paper
• Ubiquitin specific protease 2 acts as a key modulator for the regulation of cell cycle by adiponectin and leptin in cancer cells.

  2015cites this paper
• The Role of CDK4/6 Inhibition in Breast Cancer.

  2015cites this paper
• RelA-Induced Interferon Response Negatively Regulates Proliferation

  2015cites this paper
• Cyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics

  2015cites this paper
• Cyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics

  2015cites this paper
• Potential Clinical Uses of CDK Inhibitors: Lessons from Synthetic Lethality Screens

  2015cites this paper
• p19Ink4d Is a Tumor Suppressor and Controls Pituitary Anterior Lobe Cell Proliferation

  2014cites this paper
• Étude sur les fonctions in vivo des GEFs DOCK chez les mammifères

  2014cites this paper
• Overview of cyclins D1 function in cancer and the CDK inhibitor landscape: past and present

  2014cites this paper
• Cyclin-dependent kinase 4/6 inhibitors in breast cancer therapy

  2014cites this paper
• Discovery of 8-Cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a Potent Inhibitor of Cyclin-Dependent Kinase 4 (CDK4) and AMPK-Related Kinase 5 (ARK5)

  2014cites this paper
• Bifunctional up-converting lanthanide nanoparticles for selective in vitro imaging and inhibition of cyclin D as anti-cancer agents.

  2014cites this paper
• D-type Cyclins are important downstream effectors of cytokine signaling that regulate the proliferation of normal and neoplastic mammary epithelial cells.

  2014cites this paper
• Cdk4 and Nek2 Signal Binucleation and Centrosome Amplification in a Her2+ Breast Cancer Model

  2013cites this paper
• Cell cycle regulators cyclin D1 and CDK4/6 have estrogen receptor-dependent divergent functions in breast cancer migration and stem cell-like activity

  2013cites this paper
• Silencing CDK4 radiosensitizes breast cancer cells by promoting apoptosis

  2013cites this paper
• Prevention of Familial Adenomatous Polyp Development in APCmin Mice and Azoxymethane-Induced Colon Carcinogenesis in F344 Rats by ω-3 Fatty Acid Rich Perilla Oil

  2013cites this paper
• Alteration in apoptosis and cell cycle by celecoxib and/or fish oil in 7,12-dimethyl benzene (α) anthracene-induced mammary carcinogenesis

  2013cites this paper
• Assembly, activation, and substrate specificity of cyclin D1/Cdk2 complexes.

  2013cites this paper
• The prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancer

  2013cites this paper
• A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis

  2013cites this paper
• Cyclo-Oxygenase-2 and its Inhibition in Cancer

  2012cites this paper
• Cyclins and cell cycle control in cancer and disease.

  2012cites this paper
• CDK4: A Key Player in the Cell Cycle, Development, and Cancer.

  2012cites this paper
• The requirement for cyclin D function in tumor maintenance.

  2012cites this paper
• Discovery of ErbB 2

  2012cites this paper
• Effect of Fish Oil on Levels of R- and S-Enantiomers of 5-, 12-, and 15-Hydroxyeicosatetraenoic Acids in Mouse Colonic Mucosa

  2012cites this paper
• Docosahexaenoic fatty acid (DHA) in the regulation of colon cell growth and cell death: a review.

  2012cites this paper
• Vascular development and safeguard mechanisms against tumorigenesi s: oncogene-induced apoptosis and cellular senescence

  2012cites this paper
• The mechanisms of reversal of refractory dysplasia in the salivary gland: Testing the role of p53, RXR and PPARgamma agonists, and PD0332991

  2012cites this paper
• Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.

  2012cites this paper
• Cytidine Deaminases are Regulators of Estrogen Receptor Activity in Breast Cancer Cells

  2012cites this paper
• Cdk2-null mice are resistant to ErbB-2-induced mammary tumorigenesis.

  2011cites this paper
• Therapeutic strategies for targeting ras proteins.

  2011cites this paper
• ErbB2/HER2: Its Contribution to Basic Cancer Biology and the Development of Molecular Targeted Therapy

  2011cites this paper
• The G1 phase Cdks regulate the centrosome cycle and mediate oncogene-dependent centrosome amplification

  2011cites this paper
• Updating the Mammalian Cell Cycle: The Role of Interphase Cdks in Tissue Homeostasis and Cancer

  2011cites this paper
• Two faces of evil : cancer and neurodegeneration

  2011cites this paper
• Reviewing once more the c-myc and Ras collaboration

  2011cites this paper
• Potential applications of fish oils rich in n-3 fatty acids in the palliative treatment of advanced pancreatic cancer.

  2011cites this paper
• Cyclin D3 is dispensable for human diffuse large B-cell lymphoma survival and growth: evidence for redundancy with cyclin E

  2010cites this paper
• CDK inhibitors: from the bench to clinical trials.

  2010cites this paper
• Cyclin-dependent kinase 4/6 (cdk4/6) inhibitors: perspectives in cancer therapy and imaging.

  2010cites this paper
• Kip3-ing kinetochores clustered

  2010cites this paper
• A role for Cdk4 in angiogenesis

  2010cites this paper
• Requirement of Cdk4 for v-Ha-ras-Induced Breast Tumorigenesis and Activation of the v-ras-Induced Senescence Program by the R24C Mutation.

  2010cites this paper
• Phosphorylation of Cdk2 at Threonine 39 by Akt Facilitates Cyclin-CDK2 Activation

  2010cites this paper
• The Ras oncogene signals centrosome amplification in mammary epithelial cells through cyclin D1/Cdk4 and Nek2

  2010cites this paper
• Die Cyclin-abhängigen Kinasen 4 und 6 als Zielproteine für die Therapie und Bildgebung von Tumoren

  2010cites this paper
• Exploring the Gain of Function Contribution of AKT to Mammary Tumorigenesis in Mouse Models

  2010cites this paper
• Plant-Derived Antioxidants and Use in Prevention and Treatment of Prostate Cancer

  2010cites this paper
• Caracterització metabòlica de la transformació i la progressió tumoral i anàlisi de l'efecte de nous compostos amb potencial terapèutic

  2010cites this paper
• A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration.

  2010cites this paper
• Cdk2 and Cdk4 Regulate the Centrosome Cycle and Are Critical Mediators of Centrosome Amplification in p53-Null Cells

  2009cites this paper
• Emerging roles of E2Fs in cancer: an exit from cell cycle control

  2009cites this paper
• PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

  2009cites this paper
• Nuclear cyclin D1: An oncogenic driver in human cancer

  2009cites this paper
• Cell cycle, CDKs and cancer: a changing paradigm

  2009cites this paper
• Cell cycle kinases as therapeutic targets for cancer

  2009cites this paper
• Prevention and Treatment of Pancreatic Cancer by Curcumin in Combination With Omega-3 Fatty Acids

  2008cites this paper
• High-risk HPV/ErbB-2 interaction on E-cadherin/catenin regulation in human carcinogenesis.

  2008cites this paper
• Cyclin-Dependent Kinases and Their Regulators as Potential Targets for Anticancer Therapeutics

  2008cites this paper
• Opposing Effects of n-6 and n-3 Polyunsaturated Fatty Acids on Pancreatic Cancer Growth

  2008cites this paper
• Cyclin-dependent kinase 3-mediated activating transcription factor 1 phosphorylation enhances cell transformation.

  2008cites this paper